Compare · SI vs WST
SI vs WST
Side-by-side comparison of Shoulder Innovations Inc. (SI) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SI and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $22.22B, about 75.0x SI ($296.1M).
- Over the past year, SI is down 5.9% and WST is up 43.0% - WST leads by 48.9 points.
- WST has been more active in the news (4 items in the past 4 weeks vs 1 for SI).
- SI has more recent analyst coverage (25 ratings vs 16 for WST).
- Company
- Shoulder Innovations Inc.
- West Pharmaceutical Services Inc.
- Price
- $14.20-1.53%
- $320.15+1.83%
- Market cap
- $296.1M
- $22.22B
- 1M return
- +10.16%
- -0.56%
- 1Y return
- -5.90%
- +43.03%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2025
- News (4w)
- 1
- 4
- Recent ratings
- 25
- 16
Shoulder Innovations Inc.
Silvergate Capital Corporation operates as a bank holding company for Silvergate Bank that provides banking products and services to business and individual clients in the United States and internationally. The company accepts deposit products, including interest and noninterest bearing demand accounts, money market and savings accounts, and certificates of deposit accounts. Its loan products comprise one-to-four family real estate loans, multi-family real estate loans, commercial real estate loans, construction loans, commercial and industrial loans, mortgage warehouse loans, and reverse mortgage loans, as well as consumer loans and other loans secured by personal property. The company also provides cash management services for digital currency-related businesses. The company was founded in 1988 and is headquartered in La Jolla, California.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest SI
- Shoulder Innovations to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
- SEC Form 10-Q filed by Shoulder Innovations Inc.
- Shoulder Innovations Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Shoulder Innovations Reports First Quarter 2026 Financial Results and Raises Full Year Outlook
- CEO & Executive Chairman Ball Robert Joseph exercised 10,000 shares at a strike of $2.48, increasing direct ownership by 3% to 300,018 units (SEC Form 4)
- SEC Form DEF 14A filed by Shoulder Innovations Inc.
- SEC Form DEFA14A filed by Shoulder Innovations Inc.
- Shoulder Innovations Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Shoulder Innovations Initiates Full Commercial Launch of the InSet™ I-135RFX Humeral Stem
- Shoulder Innovations to Report First Quarter 2026 Financial Results on May 13, 2026
Latest WST
- Wolfe Research resumed coverage on West Pharm with a new price target
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SVP, Proprietary Segment Campbell Shane Alden covered exercise/tax liability with 219 shares and converted options into 770 shares, increasing direct ownership by 881% to 613 units (SEC Form 4)
- SEC Form SD filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Director Pucci Paolo was granted 791 shares, increasing direct ownership by 7% to 11,854 units (SEC Form 4)
- Director Michels Douglas A was granted 791 shares, increasing direct ownership by 2% to 46,496 units (SEC Form 4)
- Director Lockhart Stephen H was granted 791 shares, increasing direct ownership by 29% to 3,523 units (SEC Form 4)